Adaptive Biotechnologies to Report First Quarter Financial Results on May 4, 2022
05 avr. 2022 16h30 HE
|
Adaptive Biotechnologies
SEATTLE, April 05, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT) a commercial-stage biotechnology company that aims to translate the genetics of the adaptive immune...
Adaptive Biotechnologies Appoints Tycho Peterson as Chief Financial Officer, Reorganizes and Streamlines Workforce to Drive Growth in Two Key Business Areas
09 mars 2022 07h00 HE
|
Adaptive Biotechnologies
SEATTLE, March 09, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial-stage biotechnology company that aims to translate the genetics of the adaptive immune...
Adaptive Biotechnologies to Present at the 42nd Annual Cowen Healthcare Conference
02 mars 2022 16h05 HE
|
Adaptive Biotechnologies
SEATTLE, March 02, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the...
Adaptive Biotechnologies Announces New Data Demonstrating ImmunoSEQ® Technology Can Identify T-Cell Receptors Associated with Crohn’s Disease
18 févr. 2022 11h35 HE
|
Adaptive Biotechnologies
Data being presented at the 17th European Crohn’s and Colitis Organisation (ECCO) exhibit the use of Adaptive’s ImmunoSEQ® technology to successfully identify T-cell receptors (TCR) associated with...
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2021 Financial Results
15 févr. 2022 16h05 HE
|
Adaptive Biotechnologies
SEATTLE, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the...
Adaptive Biotechnologies to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
02 févr. 2022 16h05 HE
|
Adaptive Biotechnologies
SEATTLE, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the...
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2021 Financial Results on February 15, 2022
24 janv. 2022 16h05 HE
|
Adaptive Biotechnologies
SEATTLE, Jan. 24, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune...
Adaptive Biotechnologies Announces Preliminary, Unaudited 2021 Revenue Results and CFO Transition
10 janv. 2022 08h30 HE
|
Adaptive Biotechnologies
SEATTLE, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT) today reported preliminary, unaudited revenue for the year ended December 31, 2021. Total revenue for...
Updated: Adaptive Biotechnologies to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference
04 janv. 2022 16h05 HE
|
Adaptive Biotechnologies
SEATTLE, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the...
Adaptive Biotechnologies to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference
29 déc. 2021 08h00 HE
|
Adaptive Biotechnologies
SEATTLE, Dec. 29, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the...